Sex differences in pharmacokinetics and toxicity of antiretroviral therapy

Bibliography

• CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC): Heterosexual Tranmission Of HIV 29 States, 1999-2002. MMWR Morb. Mortal. Wkly Rep. (2004) 53(06):125-129.
   Google Scholar
• GULICK RM, RIBAUDO HJ, SHIKUMACM etal.: Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N. Engl. J. Med. (2004) 350(18):1850-1861.
   PubMed Web of Science ®Google Scholar
• GIFFORD AL, CUNNINGHAM WE, HESLIN KC etal.: Participation in research and access to experimental treatments by HIV-infected patients. N. Engl. J. Med. (2002) 346(18):1373-1382.
   PubMed Web of Science ®Google Scholar
• ANDERSON PL, KAKUDA TN, KAWLES, FLETCHER CV: Antiviral dynamics and sex differences of zidovudine and lamivudine triphosphate concentrations in HIV-infected individuals. AIDS (2003) 17(15):2159-2168.
   PubMed Web of Science ®Google Scholar
• ZHOU XJ, SHEINER LB, DAQUILA RT etal.: Population pharmacokinetics of nevirapine, zidovudine and didanosine in human immunodeficiency virus-infected patients. The National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators. Antimicrob. Agents Chemother. (1999) 43(1):121-128.
   PubMed Web of Science ®Google Scholar
• LA PORTE C, BURGER D, GYSSENS I, SPRENGER H, KOOPMANS P: Gender differences in nevirapine pharmacokinetics, fact or fiction? Proceedings of the 4th International Workshop on Clinical Pharmacology of HIV therapy. Cannes, France (2003):Abstract 3.1.
   Google Scholar
• BURGER DM, LA PORTE CJL, VANDER ENDE ME, MIESEN WMA, KOOPMANS PP: Gender-related differences in efavirenz pharmacokinetics. Proceedings of the 4th International Workshop on Clinical Pharmacology of HIV therapy. Cannes, France (2003):Abstract 3.6.
   Google Scholar
• PFISTER M, LABBE L, HAMMER SM etal.: Population pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir, and indinavir: Adult AIDS Clinical Trial Group Study 398. Antimicrob. Agents Chemother. (2003) 47(1):130-137.
   PubMed Web of Science ®Google Scholar
• BERTZ R, LAM W, HSU A, GRANNEMAN GR, SUN E: Effects of gender, race, age and weight on the pharmacokinetics of lopinavir (lopinavir/ritonavir) in healthy adult subjects after single-dose kaletra. Proceedings of the 2nd International Workshop on Clinical Pharmacology of HIV therapy. Noordwijk, The Netherlands (2001):Abstract 3.12.
   Google Scholar
• POIRIER JM, ZOUAI O, MEYNARD JL etal.: Lack of effect of gender, age, weight and body mass index on trough lopinavir plasma concentrations in HIV-pretreated patients treated with Kaletra. Proceedings of the 4th International Workshop on Clinical Pharmacology of HIV therapy. Cannes, France (2003):Abstract 6.12.
   Google Scholar
• BURGER DM, MULLER RJ, VAN DE LEUR MR, LA PORTE CJL: Lopinavir plasma levels are significantly higher in female than in male HIV-1 infected patients. Proceedings of the 3rd International Workshop on Clinical Pharmacology of HIV therapy. Washington DC, USA (2002):Abstract 6.5.
   Google Scholar
• GATTI G, DE PASCALIS CR, DE LUCA A etal.: Predictors of amprenavir parameters of drug exposure in heavily pretreated HIV positive patients. Proceedings of the 6th International Congress on Drug therapy in HIV infection. Glasgow, Scotland, UK (2002):Abstract P165.
   Google Scholar
• PAI MP, SCHRIEVER CA, DIAZ-LINARES M, NOVAK RM, RODVOLD KA: Sex-related differences in the pharmacokinetics of once-daily saquinavir soft-gelatin capsules boosted with low-dose ritonavir in patients infected with human immunodeficiency virus type 1. Pharmacotherapy. (2004) 24(5):592-599.
   PubMed Web of Science ®Google Scholar
• FLETCHER CV, JIANG H, BRUNDAGERC etal.: Sex-based differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials Group Study 359. J. Infect. Dis. (2004) 189(7):1176-1184.
   PubMed Web of Science ®Google Scholar
• DICKINSON L, BACK D, CHANDLERB etal.: The impact of gender on saquinavir hard-gel/ritonavir (1000/100 mg b.i.d.) pharmacokinetics and PBMC transporter expression in HIV-1 infected individuals. Proceedings of the 6th International Workshop on Clinical Pharmacology of HIV therapy. Quebec City, Canada (2005):Abstract 9.
   Google Scholar
• ROBERTSON S, FALLOON J, FORMENTINI E, ALFARO R, PENZAKS: Lack of sex-related differences in saquinavir pharmacokinetics in an HIV seronegative cohort. Proceedings of the 6th International Workshop on Clinical Pharmacology of HIV therapy. Quebec city, Canada (2005):Abstract 50.
   Google Scholar
• BURGER DM, SIEBERS MC, HUGENPW, AAMOUTSE RE, HEKSTER YA, KOOPMANS PP: Pharmacokinetic variability caused by gender: do women have higher indinavir exposure than men? J. Acquir. Immune Defic. Syndr. (2002) 29(1):101-102.
   PubMed Web of Science ®Google Scholar
• BURGER D, BOYD M, DUNCOMBE C etal.: Pharmacokinetics and pharmacodynamics of indinavir with or without low-dose ritonavir in HIV-infected Thai patients. J. Antimicrob. Chemother. (2003) 51(5):1231-1238.
   PubMed Web of Science ®Google Scholar
• RIBERA E, LOPEZ RM, DIAZ M etal.: Steady-state pharmacokinetics of a double-boosting regimen of saquinavir soft gel plus lopinavir plus mini-dose ritonavir in human immunodeficiency virus-infected adults. Antimicrob. Agents Chemother. (2004) 48(11):4256-4262.
   PubMed Web of Science ®Google Scholar
• MOULD DR, ZHANG X, NIEFORTHK, SALGO M, BUSS N, PATEL IH: Population pharmacokinetics and exposure-response relationship of enfurvirtide in treatment-experienced human immunodeficiency virus type 1-infected patients. Clin. Pharmacol. Ther. (2005) 77(6):515-528.
   PubMed Web of Science ®Google Scholar
• OFOTOKUN I, POMEROY C: Sex differences in adverse reactions to antiretroviral drugs. Top. HIV Med. (2003) 11(2):55-59.
   PubMedGoogle Scholar
• MOORE RD, FORTGANG I, KERULY J, CHAISSON RE: Adverse events from drug therapy for human immunodeficiency virus disease. Am. J. Med. (1996) 101(1):34-40.
   PubMed Web of Science ®Google Scholar
• CURRIER JS, SPINO C, GRIMES etal.: Differences between women and men in adverse events and CD4+ responses to nucleoside analogue therapy for HIV infection. The Aids Clinical Trials Group 175 Team. J. Acquir. Immune Defic. Syndr. (2000) 24(4):316-324.
   PubMed Web of Science ®Google Scholar
• SQUIRES K, GULICK R, PAVIA A etal.: Sex differences in the selection of thymidine analog regimen therapy trials (START I and START II). Proceedings of the 7th conference on Retroviruses and Opportunistic Infections. San Francisco, US (2000):Abstract 516.
   Google Scholar
• KUMAR P, RODRIGUEZ-FRENCH A, THOMPSON M etal.: Prospective study of hyperlipidemia in ART-nave subjects taking combivir/abacavir (COM/ABC), COM/nelfinavir (NFV), or stavudine (d4T)/lamivudine (3TC)/NFV (ESS40002). Proceedings of the 9th Conference on Retroviruses and Opportunistic Infections. Seattle, US (2002):Abstract 33.
   Google Scholar
• BERSOFF-MATCHA SJ, MILLER WC, ABERG JA etal.: Sex differences in nevirapine rash. Clin. Infect. Dis. (2001) 32(1):124-129.
   PubMed Web of Science ®Google Scholar
• MAZHUDE C, JONES S, MURAD S, TAYLOR C, EASTERBROOK P: Female sex, but not ethnicity, is a strong predictor of non-nucleoside reverse transcriptase inhibitor-induced rash. AIDS (2002) 16(11):1566-1568.
   PubMed Web of Science ®Google Scholar
• SANNE I, MOMMEJA-MARIN H, HINKLE J etal.: Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. J. Infect. Dis. (2005) 191(6):825-829.
   PubMed Web of Science ®Google Scholar
• SHEPARD KV: Important new safety information. Re: clarification of risk factors for severe, life-threatening and fatal hepatotoxicity with Viramune (nevirapine). Feb (2004). Dear health care professional letter.
   Google Scholar
• LUCAS GM, CHAISSON RE, MOORERD: Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann. Intern. Med. (1999) 131(2):81-87.
   PubMed Web of Science ®Google Scholar
• CURRIER JS, YETZER E, POTHOFF A etal.: Gender differences in adverse events on ritonavir intolerance. Proceedings of 1997 National Conference on Women and HIV. Pasadena, US (1997):Abstract 304.7.
   Google Scholar
• BONFANTI P, GULISANO C, RICCI E etal.: Risk factors for lipodystrophy in the CISAI cohort. Biomed. Pharmacother. (2003) 57(9):422-427.
   PubMed Web of Science ®Google Scholar
• PERNERSTORFER-SCHOEN H, JILMAB, PERSCHLER A: Sex differences in HAART-associated dyslipidemia. AIDS (2001) 15(6):725-734.
   PubMed Web of Science ®Google Scholar
• GANDHI M, AWEEKA F, GREENBLATT RM, BLASCHKE TF: Sex differences in pharmacokinetics and pharmacodynamics. Ann. Rev. Pharmacol. Toxicol. (2004) 44:499-523.
   PubMed Web of Science ®Google Scholar
• KNIGHT LC, PARKMAN HP, BROWNKL etal.: Delayed gastric emptying and decreased antral contractility in normal premenopausal women compared with men. Am. J. Gastroenterol. (1997) 92(6):968-975.
   PubMed Web of Science ®Google Scholar
• PINES A, ECKSTEIN N, DOTAN I etal.: Effect of estradiol on rat ileum. Gen. Pharmacol. (1998) 31(5):735-736.
   PubMedGoogle Scholar
• BARAONA E, ABITTAN CS, DOHMENK etal.: Gender differences in pharmacokinetics of alcohol. Alcohol. Clin. Exp. Res. (2001) 25(4):502-507.
   PubMed Web of Science ®Google Scholar
• PAINE MF, LUDINGTON SS, CHENML etal.: Do men and women differ in proximal small intestinal CYP3A or P-glycoprotein expression. Drug Metab. Dispos. (2005) 33(3):426-433.
   PubMed Web of Science ®Google Scholar
• WILSON K: Sex-related differences in drug disposition in man. Clin. Pharmcokinet. (1984) 9(3):189-202.
   PubMed Web of Science ®Google Scholar
• ANDERSON GD: Sex and racial differences in pharmacological response: where is the evidence? Pharmacogenetics, pharmacokinetics and pharmacodynamics. J. Womens Health (Larchmt) (2005) 14(1):19-29.
   PubMed Web of Science ®Google Scholar
• ZHU B, LIU ZQ, CHEN GL etal.: The distribution and gender difference of CYP3A activity in Chinese subjects. Br. J. Clin. Pharmacol. (2003) 55(3):264-269.
   PubMed Web of Science ®Google Scholar
• COTREAU MM, VON MOLTKE LL, GREENBLATT DJ: The influence of age and sex on the clearance of cytochrome P450 3A substrates. Clin. Pharmacokinet. (2005) 44(1):33-60.
   PubMed Web of Science ®Google Scholar
• ABERNETHY DR, GREENBLATT DJ, SHADER RI: Imipramine disposition in users of oral contraceptive steroids. Clin. Pharmacol. Ther. (1984) 35(6):792-797.
   PubMed Web of Science ®Google Scholar
• MINERS JO, GRGURINOVICH N, WHITEHEAD AG, ROBSON RA, BIRKETT DJ: Influence of gender and oral contraceptive steroids on the metabolism of salicylic acid and acetylsalicylic acid. Br. J. Clin. Pharmacol. (1986) 22(2):135-142.
   PubMed Web of Science ®Google Scholar